Impax Pharmaceuticals Reports Positive Results of Phase II Trial of IPX066, a Novel Formulation of Carbidopa-Levodopa for Par...
September 21 2009 - 8:00AM
Business Wire
Impax Pharmaceuticals, the brand products division of Impax
Laboratories, Inc. (NASDAQ: IPXL) today reported the positive
results from a recently completed Phase II trial of its late-stage
Parkinson’s Disease drug candidate IPX066
In this cross-over trial, IPX066 reduced subjects’ “off” time
during waking hours by 2 hours compared to Sinemet (3.8 hours of
“off” time for IPX066 vs. 5.8 hours for Sinemet, P
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From Jul 2023 to Jul 2024
